OR WAIT null SECS
August 24, 2020
Catalent will manufacture drug substance for AZD1222 at its Harmans, MD facility.
The Phase II trial is a randomized, placebo-controlled, observer-blinded study that will include patients aged 18 to 84 years.
August 21, 2020
CDMO Avid Bioservices will provide development and drug substance manufacturing for Oragenics’ novel COVID-19 vaccine candidate, Terra CoV-2.
August 19, 2020
Plastic primary packaging could help prevent supply chain shortages associated with high demand for COVID-19 vaccines.
August 13, 2020
SK bioscience will manufacture the vaccine antigen component for use in the final drug product at its vaccine facility in Andong L-house, South Korea.
In combination with BARDA’s previous award, the commitment for early access to Moderna’s vaccine candidate has now reached to up to $2.48 billion.
August 11, 2020
The companies will collaborate on the manufacturing, clinical development, and regulatory activities for Novavax’s COVID-19 vaccine in Japan.
The CDMO will offer capacity for manufacturing and distributing COVID-19 vaccines and therapeutics at its Grand Rapids, MI, fill/finish facility.
August 07, 2020
Sanofi and GlaxoSmithKline have been selected to supply the US government and the European Union with millions of doses of their COVID-19 vaccine candidate.
The company is working to ensure broad global access to its COVID-19 vaccine candidate, following approval from regulators.